Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Immune targeting of the microenvironment in classical Hodgkin lymphoma

Catherine Diefenbach • 19 Jun 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Acimtamig Brentuximab vedotin Checkpoint inhibitors Ipilimumab Nivolumab
E4412

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the immune targeting of the microenvironment in classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Catherine Diefenbach

A Phase Ib study of venetoclax plus Pola-R-CHP in the frontline for patients with DLBCL
2:41
A Phase Ib study of venetoclax plus Pola-R-CHP in the frontline for patients with DLBCL
Catherine Diefenbach • 7 Dec 2024
Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study
3:31
Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study
Catherine Diefenbach • 7 Dec 2024
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL
1:49
A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL
Catherine Diefenbach • 7 Dec 2024
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
6:45
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
Catherine Diefenbach • 11 Dec 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Catherine Diefenbach • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Catherine Diefenbach • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Catherine Diefenbach • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Catherine Diefenbach • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals